TY - JOUR
T1 - Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea
T2 - The naturalistic evaluation of hypoglycemic events in diabetic subjects study
AU - Kim, Yon Su
AU - Cho, Be Long
AU - Kim, Woo Sik
AU - Kim, Sang Hyun
AU - Jung, In Hyeon
AU - Sin, Won Yong
AU - Choi, Dong Hoon
AU - Lee, Sang Jae
AU - Lim, Chun Soo
AU - Kang, Kyung Pyo
AU - Yu, Byung Yeon
AU - Jeung, Wonju
AU - Park, Chang Gyu
N1 - Funding Information:
This study was funded by MSD Korea. Medical writing was provided by Zhiyi Li of Asclepius Analytics Ltd., with funding provided by MSD Korea, and editorial assistance was provided by Cactus Communications Pvt. Ltd., with funding provided by MSD Korea.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
AB - Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.
KW - Glycated hemoglobin A
KW - Hypoglycemia
KW - Metformin
KW - Sulfonylurea
KW - Type 2 diabetes mellitus
UR - http://www.scopus.com/inward/record.url?scp=85069763308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069763308&partnerID=8YFLogxK
U2 - 10.4082/kjfm.18.0051
DO - 10.4082/kjfm.18.0051
M3 - Article
AN - SCOPUS:85069763308
VL - 40
SP - 212
EP - 219
JO - Korean Journal of Family Medicine
JF - Korean Journal of Family Medicine
SN - 2005-6443
IS - 4
ER -